We look at recent adaptations in oncology—and how some of these changes can actually make cancer care stronger moving forward.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
The coronavirus pandemic has forced adjustments to all aspects of healthcare. On this episode of CANCER BUZZ, we look at recent adaptations in oncology—and how some of these changes can actually make cancer care stronger moving forward.
Guest: Randall A. Oyer, MD, Medical Director, Oncology Program, Penn Medicine Lancaster General Health; 2020-2021 ACCC President
Related Content:
This mini-podcast is supported by educational grants from AstraZeneca Pharmaceuticals, Merck & Co., Inc., and Pfizer Inc.
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
Decentralized clinical trial approaches, including remote consent, telehealth, local laboratory and imaging services, and more, can help reduce some of the many barriers that prevent eligible patients from participating in trials. But as the participants in ACCC’s Advancing Decentralized Clinical Trials in the Community Setting Roundtable Series emphasized, implementing DCT elements is not simply a matter of adopting new technology. Doing so successfully requires thoughtful workflows and oversight structures that consider equity, scalability, and sustainability.
